Cognitive & Neuro Regulation

Selank (Tuftsin Analogue)

For Research Use Only. Not for Human or Veterinary Use.

Overview

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) built from the immunomodulatory tetrapeptide tuftsin, extended with Pro-Gly-Pro to improve stability. In research it is studied as an anxiolytic that works through the GABAergic system without sedation, together with enkephalinase-inhibiting and immunomodulatory effects. It is typically delivered intranasally and is a research compound.

Chemical Profile

PropertyValue
CAS number129954-34-3
ClassSynthetic tuftsin analogue (heptapeptide)
Amino-acid sequenceH-Thr-Lys-Pro-Arg-Pro-Gly-Pro-OH
One-letter codeTKPRPGP (7 aa)
Molecular formulaC₃₃H₅₇N₁₁O₉
Molecular weight≈ 751.9 g/mol
Purity (HPLC)≥ 98%
AppearanceWhite to off-white lyophilized powder
Selank at a glance
Class
Synthetic tuftsin analogue
Origin
Tuftsin (IgG Fc-derived tetrapeptide) + Pro-Gly-Pro
Research status
Preclinical and clinical (Eastern Europe)
Study routes
Intranasal (primary), IV, IM
Half-life
≈ 20 min (intranasal)
Key feature
Anxiolytic without sedation

Mechanism of Action

Selank is a stabilised analogue of tuftsin. Its anxiolytic effect is studied as a benzodiazepine-independent modulation of the GABAergic system, and it also inhibits the enzyme that breaks down enkephalins (raising Met-enkephalin) and influences serotonin and dopamine systems — a profile associated with calming effects that do not cause the sedation or dependence of classic anxiolytics.

ComponentDetail
Primary targetGABAergic system (benzodiazepine-independent)
Enkephalinase inhibitionNeutral-endopeptidase inhibition → increased Met-enkephalin
Secondary targetsSerotonin (5-HT₁A/5-HT₂) and dopamine (D₂) systems
ImmunomodulationRetains tuftsin-like immune-signalling activity
BDNFModerate influence on neurotrophic signalling

Pharmacology

ParameterValue
Half-life (t½)≈ 20 min (intranasal)
Bioavailability (intranasal)High — direct nose-to-brain delivery
MetabolismProteolytic cleavage by exopeptidases
Route of administrationIntranasal, IV, IM
EliminationRenal (peptide fragments)

Research Evidence

Representative studies and their focus are named below; specific numerical outcomes are not restated here as claims.

Study typeResearch focusReference
Rodent anxiety modelsAnxiolytic activity without sedationSelank preclinical literature
Cognition / stress modelsCognitive and anti-stress effectsSelank preclinical literature
Clinical anxiety observationGeneralized-anxiety researchSelank clinical literature (Eastern Europe)

Representative reported directions from the literature (qualitative; GLP-1 entries reflect published clinical-trial results, others are reported study directions, not restated as precise product claims):

Reported direction / findingContextReference
Anxiolytic without sedationrodent anxiety modelsSelank literature
Immunomodulatory (tuftsin-like) activityimmune modelsSelank literature

For laboratory research use only. Not for human or veterinary use, diagnosis, or therapeutic application. Descriptions refer to published research contexts and are not medical or product claims.

Dosing & Reconstitution Reference

Reconstitution and handling parameters for laboratory research. Not dosing guidance for human use.

ParameterReference value
Research dose range (literature)≈ 200–600 µg per dose (intranasal), in study protocols
Reconstitution solventBacteriostatic water (0.9% benzyl alcohol)
Storage (lyophilized)−20°C, protected from light
Storage (reconstituted)2–8°C, up to ~7 days
Do not useIf the solution is cloudy or contains particulates

Safety Profile

Published research observations, provided for reference only. This material is not for human or veterinary use.

CategoryPublished observations
TolerabilityWell tolerated in reported studies
Sedation / dependenceNot reported (a stated advantage over classic anxiolytics)
Local (intranasal)Mild, transient nasal irritation possible
StatusFor research use only; not for human or veterinary application

Physicochemical Properties

PropertyValue
Physical stateWhite to off-white lyophilized powder
Solubility (water)Freely soluble
pH (reconstituted)5.0–7.0
Light sensitivityModerate
Stability (lyophilized)≥ 24 months at −20°C

Synthesis & Manufacturing

Selank is a 7-residue peptide made by Fmoc solid-phase synthesis; its three prolines and the basic lysine/arginine residues shape coupling, and it has no oxidation-sensitive residues.

StepDetail
StrategyFmoc solid-phase peptide synthesis
ResinWang resin (C-terminal acid)
CouplingHBTU / HOBt with DIPEA
CleavageTFA / TIPS / H₂O (95 : 2.5 : 2.5)
PurificationPreparative RP-HPLC (C18, TFA/ACN gradient)
  • Notes: coupling efficiency and complete Fmoc removal are monitored each cycle; hindered or repeated residues (e.g. Arg-Arg) may need double coupling.
  • Preparative RP-HPLC removes deletion and truncation impurities to reach research-grade purity; salt exchange (lyophilization from dilute HCl) removes residual TFA/acetate.
  • Critical quality attributes: correct molecular weight and low deletion-peptide content. No oxidation-sensitive residues; a robust, proline-rich peptide.

Analytical Methods

MethodParameterTypical result
RP-HPLC (C18, UV 214 nm)Purity≥ 98%
HPLC retentionC18, reversed-phase TFA/ACN gradientSingle main peak
ESI-MS (positive mode)Identity / mass[M+H]⁺ ≈ 752 Da
MALDI-TOFMass confirmation[M+H]⁺ ≈ 752 Da
Amino-acid analysisCompositionConsistent with the stated sequence
LC-MS (extracted ion)Deletion-peptide impuritiesWithin specification
Karl FischerWater content< 6%
LAL assayEndotoxinWithin specification
Ion chromatographyResidual TFA< 500 ppm

Representative RP-HPLC purity method:

  • Column: C18, 5 µm, 250 × 4.6 mm
  • Mobile phase A: 0.1% TFA in water · Mobile phase B: 0.1% TFA in acetonitrile
  • Gradient: reversed-phase TFA/ACN gradient · Flow rate: 1.0 mL/min · Detection: UV 214 nm
  • Confirmatory LC-MS: ESI positive mode ([M+H]⁺ ≈ 752 Da). No oxidation-sensitive residues; a robust, proline-rich peptide.

Stability Data

Representative stability behaviour under common storage, handling and formulation conditions.

ConditionDurationResult
Lyophilized, −20°C, dark≥ 24 monthsNo significant degradation (purity > 97%)
Lyophilized, 2–8°C, dark≥ 12 monthsMinimal degradation (purity > 95%)
Lyophilized, 25°C (accelerated)3 months< 5% degradation
Reconstituted, 2–8°C, dark7–14 daysMinor degradation
Reconstituted, 25°C24–48 hUse promptly
Light exposure (ICH Q1B)1.2 M lux·hGenerally light-stable
Freeze–thaw (−20°C ⇄ 25°C)3 cyclesAcceptable — aliquot to avoid repeats
  • Keep lyophilized powder cold, dry and light-protected; keep any solution refrigerated and protected from light.
  • Minimise freeze-thaw cycles; aliquot material used across many sessions.
  • Key factor: No oxidation-sensitive residues; a robust, proline-rich peptide.

Selected References

  • Selank (tuftsin analogue) anxiolytic and immunomodulatory research literature.
  • Reviews of tuftsin-derived regulatory peptides.

Quality & Supply

  • HPLC ≥ 98% purity with a Certificate of Analysis per batch
  • Identity confirmed by LC-MS
  • Research samples through to bulk, with worldwide delivery
  • Custom quantities and packaging on request

Need Selank — sample or bulk?

HPLC-verified, COA per batch. Tell us the quantity you need.

Request a Quote